Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia .
[Clinical Cancer Research]
6445212 M6DFZAKZ items 1 apa 0 default asc 1 161036 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-df0419849d8bdf85c43e381421108f28%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22M6DFZAKZ%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhang%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EZhang%2C%20H.%2C%20Wang%2C%20P.%2C%20Li%2C%20Z.%2C%20He%2C%20Y.%2C%20Gan%2C%20W.%2C%20%26amp%3B%20Jiang%2C%20H.%20%282021%29.%20Anti-CLL1%20chimeric%20antigen%20receptor%20T%20cell%20therapy%20in%20children%20with%20relapsed%5C%2Frefractory%20acute%20myeloid%20leukemia.%20%3Ci%3EClinical%20Cancer%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-4543%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-4543%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DM6DFZAKZ%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-CLL1%20chimeric%20antigen%20receptor%20T%20cell%20therapy%20in%20children%20with%20relapsed%5C%2Frefractory%20acute%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hui%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengfei%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuoyan%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yingyi%22%2C%22lastName%22%3A%22He%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wenting%22%2C%22lastName%22%3A%22Gan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hua%22%2C%22lastName%22%3A%22Jiang%22%7D%5D%2C%22abstractNote%22%3A%22Purpose%3A%20The%20survival%20rate%20of%20children%20with%20refractory%5C%2Frelapsed%20acute%20myeloid%20leukemia%20%28R%5C%2FR-AML%29%20by%20salvage%20chemotherapy%20is%20minimal.%20Treatment%20with%20chimeric%20antigen%20receptor%20T%20cells%20%28CAR-T%29%20has%20emerged%20as%20a%20novel%20therapy%20to%20improve%20malignancies%20treatment.%20C-type%20lectin-like%20molecule%201%20%28CLL1%29%20is%20highly%20expressed%20on%20AML%20leukemia%20stem%20cells%2C%20blast%20cells%2C%20and%20monocytes%2C%20but%20not%20on%20normal%20hematopoietic%20stem%20cells%2C%20indicating%20the%20therapeutic%20potential%20of%20anti-CLL1%20CAR-T%20in%20AML%20treatment.%20This%20study%20aimed%20to%20test%20the%20safety%20and%20efficacy%20of%20CAR-T%20cell%20therapy%20in%20R%5C%2FR-AML.%20Experimental%20Design%3A%20Four%20pediatric%20patients%20with%20R%5C%2FR-AML%20were%20enrolled%20in%20the%20ongoing%20phase%201%5C%2F2%20anti-CLL1%20CAR-T%20cell%20therapy%20trial.%20The%20CAR%20design%20was%20based%20on%20an%20apoptosis-inducing%20gene%2C%20FKBP-caspase%209%2C%20to%20establish%20a%20safer%20CAR%20%284S-CAR%29%20application.%20Anti-CLL1%20CAR%20was%20transduced%20into%20peripheral%20blood%20mononuclear%20cells%20of%20the%20patients%20via%20lentivector%204SCAR%2C%20followed%20by%20infusion%20into%20the%20recipients%20after%20lymphodepletion%20chemotherapy.%20Cytokine%20release%20syndrome%2C%20immune%20effector%20cell-associated%20neurotoxicity%20syndrome%2C%20and%20other%20adverse%20events%20were%20documented.%20Treatment%20response%20was%20evaluated%20by%20morphology%20and%20flow%20cytometry-based%20minimal%20residual%20disease%20assays.%20Results%3A%20Three%20R%5C%2FR-AML%20patients%20achieved%20complete%20remission%20and%20minimal%20residual%20disease%20negativity%2C%20while%20the%20other%20patient%20remained%20alive%20for%20five%20months.%20All%20these%20patients%20experienced%20low-grade%20and%20manageable%20adverse%20events.%20Conclusions%3A%20Based%20on%20our%20single-institution%20experience%2C%20autologous%20anti-CLL1%20CAR-T%20cell%20therapy%20has%20the%20potential%20to%20be%20a%20safe%20and%20efficient%20alternative%20treatment%20for%20children%20with%20R%5C%2FR-AML%2C%20and%20therefore%20requires%20further%20investigation.%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-20-4543%22%2C%22ISSN%22%3A%221078-0432%2C%201557-3265%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fclincancerres.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F04%5C%2F07%5C%2F1078-0432.CCR-20-4543%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-09T16%3A35%3A52Z%22%7D%7D%5D%7D
Zhang, H., Wang, P., Li, Z., He, Y., Gan, W., & Jiang, H. (2021). Anti-CLL1 chimeric antigen receptor T cell therapy in children with relapsed/refractory acute myeloid leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-4543 Cite
